Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents

• Main Authors: Aurpibul L., Lumbiganon P., Hansudewechakul R., Kanjanavanit S., Bunupuradah T., Kosalaraksa P., Taeprasert P., Puthanakit T.
• Format: Journal
• Published: 2017
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85007247655&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/40623
• Institution: Chiang Mai University

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. We determined hepatitis B virus (HBV) suppression rates among 18 lamivudine (3TC)-experienced HBV-human immunodeficiency virus-coinfected adolescents after treatment with tenofovir disoproxil fumurate (TDF). At TDF initiation, their m...